So in general, really blinatumomab was very well tolerated. There were some more cytopenias in some of the patients with ...

Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...

The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...

Researchers found that the outcomes were excellent for the 178 end of first consolidation measurable residual disease (MRD)-negative patients, regardless of MRD results at later time points. HealthDay ...

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Adding Iclusig (ponatinib ...

Please provide your email address to receive an email when new articles are posted on . Those who sustained MRD negativity for more than 6 months achieved longer response duration and PFS. All ...

(RTTNews) - Johnson & Johnson (JNJ) announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) significantly increased ...